Panacea Biotec Ltd. — Capital/Financing Update 2020

Oct 6, 2020

October 06, 2020

IhhOV~i"Oh l"n sapport: of tife

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO

BSE Limited

Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Scheme of Arrangement between Panacea Biotec Limited ("Demerged Company") and Ravinder Heights Limited ("Resulting Company") and their respective shareholders and creditors

Dear Sir/Madam,

This is in continuation to our earlier communications dated September 10, 2020 intimating the sanction of Scheme of Arrangement for demerger of real estate business of Panacea Biotec Limited ("Demerged Company") with and into Ravinder Heights Limited ("Resulting Company") and their respective shareholders and creditors in terms of sections 230 to 232 & section 66 and other applicable provisions of the Companies Act, 2013 ("Scheme") by Hon'ble National Company Law Tribunal, Chandigarh vide its Order dated September 09,2020 and fixation of September 22, 2020 as the Record Date.

In furtherance to the same and in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that pursuant to the Scheme, the Resulting Company in its Board Meeting held on October 06,2020 has issued and allotted 6,12,50,746 Equity Shares of Re.1 each and 1,63,000 0.5% cumulative non-convertible and non-participating redeemable preference shares of Rs.1 0/- each to the equity and preference shareholders of the Company, respectively, whose names appeared in the register of members / record of the depositories as a beneficial owner as on the Record Date i.e. September 22, 2020 in the following manner:

• I. 1 (One) equity share of face value of Re.1/- each in the Resulting Company, credited as fully paid-up for every 1 (One) equity share of face value of Re.lI- held in the Demerged Company; and
• 1. 1 (One) 0.5% cumulative non-convertible and non-participating preference share of face value of Rs.lO/ each in the Resulting Company, credited as fully paid-up for every 100 (One Hundred) preference shares (i.e. 0.5% cumulative non-convertible and non-participating Redeemable Preference Share) of face value ofRs. 1 0/- held in the Demerged Company.

The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange ofIndia Limited (NSE), subject to requisite approvals of Exchanges/SEBI.

We request you to kindly take the above on record.

Thanking you,

Yours truly,

For Panacea Biotec Limited

r-, y~ ~ VinodGoel Group CFO and Head Legal

& Company Secretary B1 Extn./G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: 0.1.0. +91-11-4167 9015 Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB 1984PLC022350 Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906. e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com